{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:01:57Z","timestamp":1755219717906,"version":"3.43.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clinthera.2025.04.002","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:53:55Z","timestamp":1746201235000},"page":"519-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Duodenal Ulcer in a Child With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Casual Association or a Possible Adverse Event?"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-4424","authenticated-orcid":false,"given":"Vito","family":"Terlizzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina Di","family":"Benedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Renzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Galici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Scarallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen G.","family":"Mainz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.04.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251323194","article-title":"Cystic fibrosis: new challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor","volume":"19","author":"Terlizzi","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0002","article-title":"Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians","volume":"54","author":"Terlizzi","year":"2024","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0003","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0004","article-title":"Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis","author":"Cecchetti","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported adverse events in a multicenter cohort of patients ages 6\u201318 years with cystic fibrosis and at least one F508del allele receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"274","author":"Terlizzi","year":"2024","journal-title":"J Pediatr"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0007","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jcf.2023.09.009","article-title":"Standards for the care of people with cystic fibrosis (CF)","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjms.2024.09.001","article-title":"Low prevalence of peptic ulcer disease in hospitalized patients with cystic fibrosis: a national database study","volume":"369","author":"Mahmoud","year":"2025","journal-title":"Am J Med Sci"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.04.002_bib0009","first-page":"268","article-title":"Duodenal intracellular bicarbonate and the \u2018CF paradox\u2019","volume":"2","author":"Kaunitz","year":"2001","journal-title":"JOP"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0010","doi-asserted-by":"crossref","first-page":"G753","DOI":"10.1152\/ajpgi.00130.2005","article-title":"A novel small molecule CFTR inhibitor attenuates HCO3- secretion and duodenal ulcer formation in rats","volume":"289","author":"Akiba","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jcf.2012.11.001","article-title":"Cystic fibrosis, gastroduodenal inflammation, duodenal ulcer, and H. pylori infection: the \u201ccystic fibrosis paradox\u201d revisited","volume":"12","author":"Ramos","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0012","article-title":"The novel CFAbd-Score.kid\u00a9 reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor\/Tezacaftor\/Ivacaftor \u2013 first result","author":"Mainz","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0013","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and calprotectin over one year of treatment with elexacaftor-tezacaftor-ivacaftor in people with CF aged \u226512 years\u2014the RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.04.002_bib0014","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Promise Study Group. Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825001213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:54:27Z","timestamp":1754553267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825001213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0149291825001213"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duodenal Ulcer in a Child With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy: A Casual Association or a Possible Adverse Event?","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}